|
Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208. |
|
|
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche |
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Ono Pharmaceutical; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Ono Pharmaceutical; Eisai; Ipsen; MSD; Novartis; PharmaEngine; Roche; TTY Biopharm |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech |
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Ipsen (Inst); Johnson & Johnson (Inst); Kintor Pharmaceutical (Inst); Merck Serono (Inst); MSD (Inst); Nucana (Inst); Roche (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - BeiGene Beijing |
Stock and Other Ownership Interests - BeiGene |
Travel, Accommodations, Expenses - BeiGene Beijing |
|
|
Employment - BeiGene; Turning Point Therapeutics (I) |
Stock and Other Ownership Interests - BeiGene; Turning Point Therapeutics (I) |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
No Relationships to Disclose |